anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A pharmaceutical drug sample tracking and control method. Pharmaceutical drug manufacturers send pharmaceutical drug samples bearing pharmaceutical drug sample indicia to dispensing locations where an indicia reader is used to read the pharmaceutical drug sample indicia into a dispensing location database. As pharmaceutical drug samples are dispensed to patients, an indicia reader is used to read the pharmaceutical drug sample indicia on pharmaceutical drug samples thus dispensed into the dispensing location database. Inventory software tracks inventory levels by subtracting pharmaceutical drug samples dispensed to patients from the previous recorded inventories. Pharmaceutical drug manufacturers can access inventory levels at dispensing locations remotely. Practitioners enter patient information, practitioner information, adverse reaction information and patient outcomes in the dispensing location database. Interested parties can access this information. Pharmaceutical drug manufacturers may instruct an intermediary to determine patient test group lists, patient newsletter lists, and lists of patients to whom drug recall and/or advisory information should be sent, and may further instruct the intermediary to send appropriate invitations, newsletters, and information to such patients, thereby maintaining patient confidentiality.
Ectoparasiticide veterinary composition comprising a nutraceutical sourced from Allium sativum (garlic) (I) An ectoparasiticide veterinary composition comprising a nutraceutical sourced from Allium sativum (garlic) which comprises at least one diallyl polysulfide compound of formula (I) wherein n is at least 4, and R1 is a substituent as herein defined, is provided. Preferably the composition comprises at least one compound of formula (I) in which n is between 7 and 22. The composition may further comprise acetic acid. The pH of the composition is preferably between 4 and 6. The composition may further comprise one or more of allyl methyl disulphide, dimethyl trisulphide, allyl-1-propenyl disulphide, allyl-1-propenyl trisulphide, 2-vinyl-4H-1,3-dithine, methyl-2-propenyl thiosulphinate. The composition is useful in the treatment, prevention or control of ectoparasitic infestations of animals; the treatment, prevention or control of stress related behaviour of animals resulting from ectoparasitic infestations; the treatment, prevention of control of bacteria infestations on a host animal; or in the maintenance and/or improvement of an immune system of an animal.
Attention-deficit/hyperactivity disorder (ADHD) is the most common childhood psychiatric disorder, present in between 3 to 10% of children in the United States (Wender et al 2001). It is thought to reflect subtle anomalies in the central nervous system and thus structural neuroimaging has been used extensively to delineate the neurobiology of the disorder. Magnetic resonance imaging has demonstrated structural anomalies in ADHD, affecting all the major lobes with particularly severe volume reductions in the cerebellum and relative preservation of the caudate nucleus (for a review see Durston 2003). In structural neuroimaging work, studies with monozygotic twins who are discordant for the disorder have proved a particularly powerful tool, with findings of a significantly smaller caudate nucleus in the affected twin compared to the unaffected, but genetically identical, twin (Castellanos et al 2003). We have previously reported an overall reduction in white matter volume in all four major brain lobes, with the deficit appearing to be fixed and non-progressive. However, recent advances in neuroimaging of white matter make feasible an examination of white matter characteristics, such as the degree of myelination and the coherence of white matter tracts. The proposed project builds on our anatomic magnetic resonance imaging (MRI) studies that have been performed with a 1.5-Tesla scanner in children who have Attention-Deficit/Hyperactivity Disorder (ADHD) and normal controls. We now propose to use diffusion tensor magnetic resonance imaging (DT-MRI) as conventional T(1)- and T(2)-weighted images at 3-Tesla to visualize and quantify white matter tracts in the brains of normal monozygotic (MZ) twins, MZ twins who are concordant for ADHD, and MZ twins who are discordant for ADHD. Ages will range from 6 to 21 years. Our principal focus will be on development and possible abnormalities of white matter tracts linking prefrontal-striatal-thalamic circuits in which we hypothesize disruption of these tracts in affected twins relative to their healthy co-twins. We will also explore the usefulness of this technique in delineating white matter in cerebellar circuits and characterize the normal development of white matter from ages 6 to 21 by using a single healthy twin per family.
BACKGROUND: Robot-assisted radical prostatectomy (RARP) gains increasing popularity in the surgical management of prostate cancer (PCa) but is challenged by its prohibitive expense. A domestic robotic system has been developed to address this issue, but data comparing the self-developed robot with the widely used robot is lacking. We performed a randomized clinical trial to compare KD-SR-01® and DaVinci® robots in terms of perioperative, short-term oncological and functional outcomes in RARP.
MATERIALS AND METHODS: We prospectively enrolled patients with clinically localized PCa. Patients were randomized to undergo either KD-SR-01®-RARP (K-RARP) or DaVinci®-RARP (D-RARP) by the same surgical team. The baseline, perioperative, short-term oncologic and urinary functional data were collected and compared.
RESULTS: We enrolled 39 patients, including 20 patients undergoing K-RARP and 19 undergoing D-RARP. Demographic and tumor characteristics were comparable between groups. All surgeries were performed successfully with no conversion to open. The operative time was similar (P = 0.095) and K-RARP offered less volume of intraoperative bleeding (P < 0.001). Four patients in the K-RARP group and three in the D-RARP group developed postoperative complications (P = 0.732). Patients undergoing K-RARP had less volume of drainage (P = 0.022). Positive surgical margins were observed in three patients undergoing K-RARP and five undergoing D-RARP (P = 0.451). During the follow up, one patient receiving K-RARP group and two receiving D-RARP group had measurable prostate specific antigen (P = 0.605). Urine leakage, urinary control and pad usage were comparable between groups at six weeks post-surgery.
CONCLUSIONS: The two surgical robots yielded similar results in feasibility, safety and short-term oncologic and functional efficacy for RARP.
TRIAL REGISTRATION: The trial has been registered at www.chictr.org.cn with a registration number of ChiCTR2200057000 on 25th February 2022.
AMS may occur infrequently with IGIV treatments including BIVIGAM. AMS usually begins within several hours to 2 days following IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae. 7,8,9

AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting ( see  Patient Counseling Information [17.3]). Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting such signs and symptoms, including CSF studies, to rule out other causes of meningitis. 

AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV.
PURPOSE:To provide a crude drug composition containing MOKKO (root of Saussurea lappa), SHOUKYOU (rhizome of Zingiber officinale), JUTSU (rhizome of Curcuma zedoaria) and KANZOU (root of Glycyrrhiza glabra), exhibiting excellent antiulcer effect against digestive tracts, extremely effective for the remedy of ulcer of digestive tracts, damage of gastric mucosa, etc., and free from side effect. CONSTITUTION:The objective agent contains 2-20wt.% (preferably 5-10wt.%) of herb drug components consisting of (A) MOKKO having central suppressing and smooth muscle relaxing action, (B) SHOUKYOU having central suppressing action and analgesic and antipyretic action, (C) JUTSU having antiulcer action to digestive tracts and blood sugar depressing action and (D) KANZOU having analgesic and antispasmodic action, antiulcer action to digestive tracts and anti-inflammatory action in the form of fluidextract or tincture. The amounts of the components B, C and D are 2-10 pts.wt., 6-14 pts.wt. and 2-8 pts.wt. per 10 pts.wt. of the component A, respectively and the dose of the composition is 100-300mg/day for adult.
In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
<P>PROBLEM TO BE SOLVED: To provide a prophylactic agent and a therapeutic agent against botulinum toxin, a method for detecting botulinum toxin, and a botulinum toxin detection kit.  <P>SOLUTION: A polypeptide is provided which is derived from the heavy chain (H chain) of botulinum toxin produced by a genetic recombination technique. A vaccine (prophylactic agent) and an antibody (therapeutic agent) can be obtained from the obtained polypeptide. In type C or type D, it is most practicable to make a vaccine by mixing the C terminal side (Hc) of its heavy chain with HA1 (or HA3b) as part of its nontoxic component. A method for detecting botulinum toxin is also provided which comprises capturing that portion of a botulinum toxin complex which is other than the botulinum toxin light chain (L chain) and reacting the captured botulinum toxin light chain (L chain) with a substrate. A test kit is further provided which utilizes a nucleic acid amplification technique using a primer set common to the botulinum toxin genes of the respective types.  <P>COPYRIGHT: (C)2009,JPO&INPIT
In both groups the "usual care" or usual treatment, will consist of the usual daily medical examinations of the department, respiratory and motor physiotherapy sessions. The Group 2, therefore, will not be submitted to other type of treatment outside of that previewed near O.U. for the course of the first three weeks, during which they will be placed on the waiting list. Once the Once the assessment is carried out after 3 weeks, we will proceed to implement the intervention proposed to the Group 1. If the participant has already been discharged from the structure, it will still be possible to proceed with the intervention, since it is online. If the participant has already been discharged from the structure, you can still proceed with the intervention, since this is in telemedicine, in order to promote the continuity hospital-territory.
In this group, patients willingly receive CT-guided percutaneous radiofrequency ablation procedures are selected according to the inclusion criteria as follows. After a series of preoperative evaluation and preoperative preparation，the procedures will be performed under the CT guidance. CT/MRI scans will be ordered after 24-48 hours to see if there are complications (such as haemorrhage, pneumothorax and pleural effusion). Regularly follow-up will be carried out for several years after RFA to assess the effectiveness and safety of RFA integratedly.
Laparoscopic Sleeve Gastrectomy (LSG), a purely restrictive procedure, has become recently one of the most popular bariatric surgical procedures in this decade because its surgical technique is simple but outcomes in regards to weight loss and co-morbidities improvement are excellent comparable to other procedures. Nevertheless, this procedure carries one potential drawback namely "gastroesophageal reflux disease (GERD). The impact on GERD following LSG are inconsistent . Additionally, the recent literature can be divided into two categories: those that support an increase in GERD prevalence after LSG and those that demonstrate a decrease in GERD prevalence after LSG. Postoperatively, one of the proposed mechanisms for either increased or decreased GERD prevalence is gastric emptying time. Delayed gastric emptying time can contribute to increase intra-gastric volume and pressure resulting in an increase in prevalence of GERD after surgery. On the other hand, accelerated gastric emptying time can cause decrease in GERD prevalence because of decrease in stomach volume and interorgan pressure after operation. In addition, LSG creates a vertical gastrectomy which results in a narrow and tubular shape of stomach. The line of resection starts at 3-6 cm. from pylorus (antrum) toward to the angle of His. The gastric antrum plays a major role in gastric emptying, particularly for solids. Hence, depending upon the starting point of gastric sleeve resection in each center, this can result in difference of the remaining gastric antrum which may affect gastric emptying time after this procedure. The investigators hypothesize that a larger amount of gastric antrum will result in accelerated gastric emptying time which leads to less GERD prevalence. On the contrary, the less the remaining gastric antrum would result in delayed gastric emptying which contribute to more GERD prevalence. The investigators plan on identifying the prevalence of GERD in the patients who undergo LSG comparing those who have the sleeve beginning either 3 cm. or 6 cm. from pylorus. We will utilize 24 hour esophageal pH monitoring, esophageal manometry, upper gastrointestinal scintigraphy and esophagogastroduodenoscopy at preoperatively, 3 and 6 month postoperatively. Ultimately, this study will help further clarify the most proper starting resected point of LSG (3 versus 6 cm. from pylorus) which results in the least GERD prevalence after surgery.
PURPOSE:To provide the titled agent exhibiting excellent hemostatic and wound- protecting activities and containing sodium polyacrylate powder having a specific average particle diameter. CONSTITUTION:The objective hemostatic and wound-protecting agent can be produced by mixing (A) powder of sodium polyacrylate having an average particle diameter of <=140mum, preferably 30-3mum (PANA which may be partially crosslinked. The average molecular weight of the polymer is >=500,000, preferably >=1,500,000 and a substitution degree of sodium is 20-100%, preferably 40-100%) and (B) a medicine useful for hemostasis and the remedy of wound (e.g. an antibacterial agent such as tetracycline, an anti-inflammatory agent such as sulpyrine, local anesthetic such as lidocaine hydrochloride) to (C) a substrate for external use. The amount of the component B is 0.01-6% for antibacterial agent, 1-40% for anti-inflammatory agent and 0.01-4% for local anesthetic based on the whole drug preparation. The agent may be added further with a water-soluble natural polymer such as collagen, gelatin, etc.
This group will participate in a structured program that combines the development of emotional intelligence with relaxation techniques. It will last 12 weeks, with sessions twice a week, each lasting approximately 60 minutes. The sessions will be led by a mental health professional. During the sessions, exercises will be worked on to recognize, understand and regulate emotions, allowing participants to develop skills to better manage stress and anxiety. In addition, relaxation techniques such as deep breathing, guided meditation and visualization will be practiced, which have been shown to be effective in reducing muscle tension, lowering cortisol levels and promoting restful sleep.
The transcranial dopplers will be carry out on 75 brain-damaged patients by 13 emergency residents physicians after a theoretical and practical training. They will be evaluated by 8 experts. The primary endpoint will be the mean number of transcranial dopplers required to have an excellent concordance between resident and expert. The concordance between the Doppler findings of the resident and the expert would exceed 0.8 before 30 examinations. The learning curve assessed on the duration necessary to acquire good quality data should decrease rapidly with the repetition of the examinations. Validating the transcranial Doppler learning curve for junior emergency physician would allow them to perform this exam safely and efficiently. Transcranial Doppler may be easy and fast to learn but the persistence of its competency over time should be evaluated.
The invention relates to 7-(a -azidophenyl-acetamido) cephalosporanic acid and non-toxic salts thereof.  Cephalosporin compounds of formula <FORM:1073530/C2/1> and their non-toxic salts, wherein R represents an organic group, are prepared by reacting 7-aminocephalosporanic acid with a silylating agent of formula <FORM:1073530/C2/2> wherein R1, R2 and R3 are alkyl groups of 1 to 6 C atoms, X is a halogen atom or a group -NR4R5 (wherein R4 is H or C1- 6 alkyl and R5 is H or C1- 6 alkyl or a group <FORM:1073530/C2/3> reacting the silylated product of the silylation with a carboxylic acid of formula R.COOH or a reactive derivative thereof, removing by hydrolysis any silyl groups and optionally converting the resulting product into a non-toxic salt.  A chlorotrialkylsilane may be used in an organic solvent in the presence of a basic tertiary amine.  Alternatively, excess of a N-trialkylsilyl-dialkylamine may be used at a temperature of 30 DEG to 170 DEG  C. with simultaneous removal of the dialkylamine by-product.  R may be alkyl, cycloalkyl, aryl, aryloxyalkyl, *?* or heterocyclic which may be substituted by one or more halogen atoms, alkyl, aryloxy, alkoxy, hydroxy, acyloxy, carboxy, carbalkoxy, alkyl mercapto, mercapto, sulphoxy, sulphonyl, nitro or amino, aminoxy oximino or alkoxyimino groups.  The amino group may be protected. Salts are formed with metals e.g. calcium and aluminium and amines e.g. procaine.
Extracellular vesicles (EVs) are small vesicles released by cells that facilitate cell signaling. They are categorized based on their biogenesis and size. In the context of the central nervous system (CNS), EVs have been extensively studied for their role in both normal physiological functions and diseases like Alzheimer's disease (AD). AD is a neurodegenerative disorder characterized by cognitive decline and neuronal death. EVs have emerged as potential biomarkers for AD due to their involvement in disease progression. Specifically, EVs derived from neurons, astrocytes, and neuron precursor cells exhibit changes in quantity and composition in AD. Neuron-derived EVs have been found to contain key proteins associated with AD pathology, such as amyloid beta (Aß) and tau. Increased levels of Aß in neuron-derived EVs isolated from the plasma have been observed in individuals with AD and mild cognitive impairment, suggesting their potential as early biomarkers. However, the analysis of tau in neuron-derived EVs is still inconclusive. In addition to Aß and tau, neuron-derived EVs also carry other proteins linked to AD, including synaptic proteins. These findings indicate that EVs could serve as biomarkers for AD, particularly for early diagnosis and disease monitoring. However, further research is required to validate their use and explore potential therapeutic applications. To summarize, EVs are small vesicles involved in cell signaling within the CNS. They hold promise as biomarkers for AD, potentially enabling early diagnosis and monitoring of disease progression. Ongoing research aims to refine their use as biomarkers and uncover additional therapeutic applications.
OBJECTIVE: Measuring health outcomes plays an important role in patient-centred healthcare. When aggregated across patients, outcomes can provide data for quality improvement (QI). However, most physical therapists are not familiar with QI methods based on patient outcomes. This mixed-methods study aimed to develop and evaluate a QI programme in outpatient physical therapy care based on routinely collected health outcomes of patients with low-back pain and neck pain.
METHODS: The QI programme was conducted by three teams of 5-6 physical therapists from outpatient settings. Plan-do-study-act cycles were used based on team-selected goals. Monthly feedback reports of process and outcomes of care, including pre-post treatment changes in Oswestry Disability Index (ODI) and Neck Disability Index (NDI), guided the QI efforts. Primary outcomes were pre-QI and post-QI changes in knowledge and attitudes towards outcome measures through a survey, and administered and self-reported compliance with using the ODI and NDI. Semistructured interviews and a focus group were conducted to evaluate the perceived value of the programme.
RESULTS: Post-QI, the survey showed improvements in two items related to the role of patients and implementation of outcome measures. Registered pre-QI and post-QI completion rates were high at intake (ODI:91% pre, 88% post; NDI:75% pre, 84% post), while completion rates at discharge improved post-QI (ODI:14% pre, 66% post; NDI: 32% pre, 50% post). Perceived benefits of the QI programme included clinician and institutional accountability to processes and strategies aimed at continuous improvement in patient care. An important facilitator for programme participation was autonomy in project selection and development, while a main barrier was the time required to set up the QI project.
CONCLUSION: A QI programme based on the feedback of routinely collected health outcomes of patients with low back pain and neck pain was feasible and well accepted by three pilot teams of physical therapists.
BACKGROUND: The company Ethnocare has developed the Overlay, a new pneumatic solution for managing volumetric variations (VVs) of the residual limb (RL) in transtibial amputees (TTAs), which improves socket fitting. However, the impact of the Overlay during functional tasks and on the comfort and pain felt in the RL is unknown.
METHODS: 8 TTAs participated in two evaluations, separated by two weeks. We measured compensatory strategies (CS) using spatio-temporal parameters and three-dimensional lower limb kinematics and kinetics during gait and sit-to-stand (STS) tasks. During each visit, the participant carried out our protocol while wearing the Overlay and prosthetic folds (PFs), the most common solution to VV. Between each task, comfort and pain felt were assessed using visual analog scales.
RESULTS: While walking, the cadence with the Overlay was 105 steps/min, while it was 101 steps/min with PFs (p = 0.021). During 35% and 55% of the STS cycle, less hip flexion was observed while wearing the Overlay compared to PFs (p = 0.004). We found asymmetry coefficients of 13.9% with the Overlay and 17% with PFs during the STS (p = 0.016) task. Pain (p = 0.031), comfort (p = 0.017), and satisfaction (p = 0.041) were better with the Overlay during the second visit.
CONCLUSION: The Overlay's impact is similar to PFs' but provides less pain and better comfort.